Serotonin activates MAP kinase and PI3K/Akt signaling pathways in prostate cancer cell lines

Urologic Oncology: Seminars and Original Investigations

Volumn 29, Issue 4, 2011, Pages 436-445

  Dizeyi, Nishtman ^a   Hedlund, Petter ^b   Bjartell, Anders ^a   Tinzl, Martina ^a   Austild Taskén, Kristin ^c   Abrahamsson, Per Anders ^a  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

^b LUND UNIVERSITY   (Sweden)

^c AKER UNIVERSITY HOSPITAL   (Norway)

Author keywords

5 HT; 5 HTR antagonist; MAPK Erk1 2; PI3K Akt; Prostate cancer

Indexed keywords

1 (2 METHOXYPHENYL) 4 (4 PHTHALIMIDOBUTYL)PIPERAZINE; 1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; 2 MORPHOLINO 8 PHENYLCHROMONE; CHROMOGRANIN A; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; NEURON SPECIFIC ENOLASE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; SEROTONIN; SEROTONIN RECEPTOR;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CANCER CELL CULTURE; CELL MIGRATION; CELL PROLIFERATION; CELL STIMULATION; CELL STRAIN DU145; CELL STRAIN LNCAP; CELL STRAIN PC 3; CONCENTRATION RESPONSE; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; IMMUNOFLUORESCENCE TEST; INTRACELLULAR SIGNALING; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; RAT; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

BLOTTING, WESTERN; BUTADIENES; CELL DIFFERENTIATION; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; CHROMONES; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; MALE; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; MORPHOLINES; NEUROSECRETORY SYSTEMS; NITRILES; PHOSPHATIDYLINOSITOL 3-KINASES; PHOSPHORYLATION; PIPERAZINES; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-AKT; SEROTONIN; SEROTONIN ANTAGONISTS; SEROTONIN RECEPTOR AGONISTS; SIGNAL TRANSDUCTION; TIME FACTORS;

EID: 79959897334     PISSN: 10781439     EISSN: 18732496     Source Type: Journal    
DOI: 10.1016/j.urolonc.2009.09.013     Document Type: Article

References (31)

1. Mosca A., Berruti A., Russo L., et al. The neuroendocrine phenotype in prostate cancer: Basic and clinical aspects. J Endocrinol Invest 2005, 28:141-145.
2. Vashchenko N., Abrahamsson P.A. Neuroendocrine differentiation in prostate cancer: Implications for new treatment modalities. Eur Urol 2005, 47:147-155.
3. Slovin S.F. Neuroendocrine differentiation in prostate cancer: A sheep in wolf's clothing. Nature Clinical Practice Urology 2006, 3:138-144.
4. Franco O.E., Onishi T., Yamakawa K., et al. Mitogen-activated protein kinase pathway is involved in androgen-independent PSA gene expression in LNCaP cells. Prostate 2003, 56:319-325.
5. Culig Z. Androgen receptor cross-talk with cell signaling pathways. Growth factors 2004, 22:179-184.
6. Hoyer D., Hannon J.P., Martin G.R. Molecular, pharmacologic, and functional diversity of 5-HT receptors. Pharmacol Biochem Behav 2002, 71:533-554.
7. Ishizuka J., Beauchamp R.D., Townsend C.M., et al. Receptor-mediated autocrine growth-stimulatory effect of 5-hydroxytryptamine on cultured human pancreatic carcinoid cells. J Cell Physiol 1992, 150:1-7.
8. Cattaneo M.G., Fesce R., Vicentini L.M. Mitogenic effect of serotonin in human small cell lung carcinoma cells via both 5-HT1A and 5-HT1D receptors. Eur J Pharmacol 1995, 291:209-211.
9. Takai D., Yagi Y., Wakazono K., et al. Silencing of HTR1B and reduced expression of EDN1 in human lung cancers, revealed by methylation-sensitive representational difference analysis. Oncogene 2001, 20:7505-7513.
10. Sonier B., Arseneault M., Lavigne C., et al. The 5-HT2A serotoninergic receptor is expressed in the MCF-7 human breast cancer cell line and reveals a mitogenic effect of serotonin. Biochem Biophys Res Commun 2006, 343:1053-1059.
11. Siddiqui E.J., Shabbir M., Mikhailidis D.P., et al. The role of serotonin (5-hydroxytryptamine1A and 1B) receptors in prostate cancer cell proliferation. J Urol 2006, 173:1648-1653.
12. Fanburg B.L., Lee S.L. A new role for an old molecule: Serotonin as a mitogen. Am J Physiol Lung Cell Mol Physiol 1997, 272:795-806.
13. Liu Y., Fanburg B.L. Serotonin-induced growth of pulmonary artery smooth muscle requires activation of PI3K/Akt/S6K1. Am J Respir Cell Mol Biol 2005, 34:182-191.
14. Dizeyi N., Bjartell A., Nilsson E., et al. Expression of serotonin receptors and role of serotonin in human prostate cancer tissue and cell lines. Prostate 2004, 59:328-336.
15. Dizeyi N., Bjartell A., Hedlund P., et al. Expression of serotonin receptors 2B and 4 in human prostate cancer tissue and effects of their antagonists on prostate cancer cell lines. Eur Urol 2005, 47:895-900.
16. Bakin R.E., Gioeli D., Sikes R.A., et al. Constitutive activation of the Ras/mitogen-activated protein kinase signaling pathway promotes androgen hypersensitivity in LNCaP prostate cancer cells. Cancer Res 2003, 63:1981-1989.
17. Bakin R.E., Gioeli D., Bissonette E.A., et al. Attenuation of Ras signaling restores androgen sensitivity to hormone-refractory C4-2 prostate cancer cells. Cancer Res 2003, 63:1975-1980.
18. Weber M.J., Gioeli D. Ras signaling in prostate cancer progression. J Cell Biochem 2004, 91:13-25.
19. Ghosh P.M., Malik S., Bedolla R., et al. Akt in prostate cancer: Possible role in androgen independence. Curr Drug Metab 2003, 4:487-496.
20. Davies M.A., Koul D., Dhesi H., et al. Regulation of AKT/PKB activity, cellular growth, and apoptosis in prostate carcinoma cells by MMAC/PTEN. Cancer Res 1999, 59:2551-2556.
21. Hsiung S.C., Tamir H., Franke T.F., et al. Roles of extracellular signal-regulated kinase and Akt signaling in coordinating nuclear transcription factor-κB-dependent cell survival after serotonin 1A receptor activation. J Neurochem 2005, 95:1653-1666.
22. Mulholland D.J., Dedhar S., Wu H., et al. PTEN and GSK3β: Key regulators of progression to androgen-independent prostate cancer. Oncogene 2006, 25:329-337.
23. Cox M.E., Deeble P.D., Bissonette E.A., et al. Activated 3',5'-cyclic AMP-dependent protein kinase is sufficient to induce neuroendocrine-like differentiation of the LNCaP prostate tumor cell line. J Biol Chem 2000, 275:13812-13818.
24. Siddiqui E.J., Thompson C.S., Mikhailidis D.P., et al. The role of serotonin in tumor growth (review). Oncol Rep 2005, 14:1593-1597.
25. Nebigil C.G., Launay J.M., Hickel P., et al. 5-Hydroxytryptamine 2B receptor regulates cell-cycle progression: Cross-talk with tyrosine kinase pathways. Proc Natl Acad Sci USA 2000, 97:2591-2596.
26. Strok P.J., Schmitt J.M. Crosstalk between cAMP and MAP kinase signaling in the regulation of cell proliferation. Trends Cell Biol 2002, 12:258-266.
27. Komiya A., Suzuki H., Imamoto T., et al. Neuroendocrine differentiation in the progression of prostate cancer. Int J Urol 2009, 16:37-44.
28. Bastola D.R., Pahwa G.S., Lin M.F., et al. Down-regulation of PTEN/MMAC/TEP1 expression in human prostate cancer cell line DU145 by growth stimuli. Mol Cell Biochem 2002, 236:75-81.
29. Pfeil K., Eder I.E., Putz T., et al. Long-term androgen-ablation causes increased resistance to PI3K/AKT pathway inhibition in prostate cancer cells. Prostate 2004, 58:259-268.
30. Griffioen A.W., Molema G. Angiogenesis: Potentials for pharmacologic intervention in the treatment of cancer, cardiovascular diseases, and chronic inflammation. Pharmacol Rev 2000, 52:237-268.
31. Shuster C.B., Herman I.M. The mechanics of vascular cell motility. Microcirculation 1998, 5:239-257.